MSF claims GSK's intervention reveals ACTA as a front to push for stronger IP rights
This article was originally published in Scrip
Executive Summary
The risks inherent in individual pharmaceutical companies raising their heads above the political parapet are illustrated by the response to GlaxoSmithKline's position paper on the Anti-Counterfeiting Trade Agreement (ACTA) from the humanitarian body Médecins Sans Frontières. GSK called for broad adoption of ACTA, a move that MSF feels reveals that ACTA is really about imposing on developing nations intellectual property rules that go beyond those established by the TRIPS agreement of World Trade Organisation.